Gilead’s potential coronavirus treatment stirs investor hopes but evidence on effectiveness is mixed

Biotech group’s shares have soared this year on hopes drug could be used to treat coronavirus

US-led trial shows positive results in hastening recovery time for coronavirus patients

Gilead Sciences announced Wednesday that more than half of the 397 severely ill coronavirus patients it treated with the antiviral Ebola drug Remdesivir were discharged from hospitals.

In an interview with Good Morning America on Thursday, Dr. Aneesh Mehta of Emory University Medical School - one of the institutions which took part in the study - spoke of its success.

The FDA may announce its decision allowing emergency use authorization of an antiviral remdesivir for coronavirus patients as early as Wednesday.

Remdesivir, an antiviral made by California-based Gilead Sciences, was shown to slash recovery times in a global trial of more than 1,000 patients, including Britons.

Gilead Sciences CEO Daniel O'Day wrote in an open letter obtained by Fox News that early results on his company's drug remdesivir's benefits for coronavirus patients offer 'hope' that's badly needed.

Gilead Sciences said Thursday in an earnings report that it is ramping up production of its antiviral remdesivir, and could make 'several million' 10-day treatment courses of the drug for 2021.

Gilead Sciences CEO Daniel O'Day told Stat News that his company understands its responsibility to make its antiviral drug affordable after it showed promise for treating coronavirus.

President Donald Trump announced Friday that the FDA has approved the drug remdesivir for emergency use in hospitalized coronavirus patients. 

Gilead Scienced, based in California, said it's in talks with 'several' generic drug makers across Europe and Asia, including India and Pakistan, to produce its experimental coronavirus drug remdesivir.

A report from a cost watchdog estimated that it costs $9.32 to manufacture one 10-day course of remdesivir treatment and that, if proven to save live, it could cost $4,500 per treatment.

While most people would be happy with an iPhone for their birthday, Larry Emdur is receiving a new electric Tesla Cybertruck.

The Morning Show host Larry Emdur is known for his affable wit. And on Saturday, the 55-year-old showed his signature good humour when he faced a giant goanna near his Sydney home.

अमेरिकी कंपनी गिलियड साइंसेज (Gilead Sciences) का दावा है कि कोरोना वायरस (COVID-19) के इलाज में Remdesivir एक कारगर दवाई साबित होगी. इस पर प्रयोग जारी हैं. आइए जानते हैं इस दवाई से जुड़ी खास जरूरी बातें.

नैटको फार्मा लिमिटेड (Natco Pharma Ltd) और लॉरस लैब्स लिमिटेड (Laurus Labs Ltd) एंटी वायर ड्रग रेमेडिसविर (Remdesivir) बनाने के लाइसेंस के लिए अमेरिकी फार्मास्युटिकल कंपनी गिलियड साइंस इंक (Gilead Sciences Inc) से बातचीत की है.

Remdesivir is authorised for the treatment of hospitalised patients with severe Covid-19 disease though the optimal duration of treatment is still being studied in ongoing clinical trials.

Remdesivir is an investigational antiviral drug that may be found effective against the virus that causes Covid-19

Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.

An experimental antiviral drug developed by a research-based biopharmaceutical company, Gilead Sciences showed positive results on its application, where more than half of a group of severely ill coronavirus patients improved. UPDATE: On 29 April, Gilead Sciences Inc. announced that in Phase

One of Bangladesh's largest drugmakers, Beximco Pharmaceuticals, will start production this month of the experimental antiviral drug remdesivir, which has shown promise in fighting the new coronavirus, a senior company executive said on Tuesday.

Schubert, Sarah Joanne, author

Recent clinical trial results and the decision by the US Food and Drug Administration to issue 'Emergency Use Authorisation' for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally, Gilead said.

Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.

Checks with industry on when can production begin here for trials

Hayden Library - PT2440.N72.E43 2014

Van Emden, Joan

Gilead Sciences' antiviral is in multiple late-stage trials to treat coronavirus infections. Don't expect a home run, say infectious disease experts

Gilead's Chief Medical Officer talks about the challenges of clinical design in the time of COVID-19

Manufacturing experts weigh in on Gilead's challenge in making its potential COVID-19 treatment

Manufacturing experts weigh in on Gilead's challenge in making its potential COVID-19 treatment

Limited results from a NIAID study suggest the drug helps people with COVID-19 recover faster

Rotch Library - NA680.T363 2018

Gilead said it was in discussions with 'some of the world’s leading chemical and pharmaceutical manufacturing companies' to produce remdesivir for Europe, Asia and the developing world through at least 2022